Igyxos S.A. has completed a Series A fundraising
Igyxos S.A. has completed a US$8.4 million fundraising as part of a Series A funding led by Bpifrance through its FABS Fund, with participation from the Go Capital Amorçage II and Loire Valley Invest Funds and by the Emergence Innovation II. This will allow the founder Marie Christine Maurel and Professor René Frydman, joined by Pierre-Henry Longeray (ex Merck Serono) as CEO, to pursue the proof of concept in human clinical practice.
Based in Nouzilly, France, biotechnology startup Igyxos is developing a new treatment for female and male infertility that works by shifting hormonal imbalances with a new method using monoclonal antibodies.
Oaklins’ team in France advised Igyxos on a "dual-track" project that allowed them to validate with the industry both scientific and therapeutic interest of its drug candidate based on the use of monoclonal antibodies to improve the treatment of female and male infertility.
Marie-Christine Maurel
CSO and Founder, Igyxos, S.A.
Sprechen Sie mit dem Deal Team
Transaktionen
Perkbox has been acquired by Great Hill Partners
Molten Ventures has sold Perkbox to Great Hill Partners.
Mehr erfahrenArculus Cyber Security has been acquired by Bridewell
The shareholders of Arculus Cyber Security (Arculus) have sold the business to Bridewell. The deal will bolster Bridewell’s growing roster of accreditations as well as strengthen its public sector footprint, enabling the expansion of its end-to-end cyber security offering for clients across the globe.
Mehr erfahrenWhite Lab has acquired Testing
White Lab Srl. has acquired Testing Srl.
Mehr erfahren